Seralutinib reduces vessel wall volume and increases small pulmonary artery vessel volume: Insights from AI-driven CT imaging analysis

Background : Vascular remodeling in PAH involves changes in vessel wall morphology. Seralutinib, an inhaled tyrosine kinase inhibitor, reduced pulmonary vascular resistance in the phase 2 TORREY study in PAH, and has the potential to target this remodeling. We applied a novel CT analysis method to quantify changes, for the first time, in vascular wall morphology associated with seralutinib. Methods : Arterial reconstructions and vascular wall metrics were computed from non-contrast chest CT scans using a neural network regressor trained on synthetic vascular trees. Metrics are BV1/BV20 (ratio of vessels